MP33-20 The SmartTarget Biopsy Trial: a Prospective Paired Blinded Trial with Randomisation to Compare Visual-Estimation and Image-Fusion Targeted Prostate Biopsies

Multi-parametric MRI targeted prostate biopsies can improve detection of clinically significant prostate cancer and decrease the diagnosis of clinically insignificant cancers. There is debate whether visual estimated targeting is sufficient or whether image-fusion software is required. We conducted an ethics committee approved, prospective, blinded, paired validating clinical trial of visual estimated targeted biopsies compared to non-rigid MR/US image-fusion using an academically developed fusion system (SmartTarget®).